









市场行情
/
股票
/
nasdaq-uthr
/

United Therapeutics Corp

UTHR

483.230USD

-7.600-1.55%

收盘 01/09, 16:00（美东）报价延迟15分钟

20.73B总市值

16.97市盈率 TTM



United Therapeutics Corp

483.230

-7.600-1.55%

概览公司财务分析

概览

公司

财务

分析

关于 United Therapeutics Corp 公司

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

United Therapeutics Corp简介



公司代码UTHR

公司名称United Therapeutics Corp

上市日期Jun 17, 1999

CEORothblatt (Martine A)

员工数量1305

证券类型Ordinary Share

年结日Jun 17

公司地址1000 Spring St

城市SILVER SPRING

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编20910

电话13016089292

网址https://www.unither.com/

公司代码UTHR

上市日期Jun 17, 1999

CEORothblatt (Martine A)

United Therapeutics Corp公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

Mr. Richard A. Giltner

Independent Director

20.57K

+1190.00%

Prof. Nilda Mesa, J.D.

Independent Director

5.29K

-187.00%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

+3200.00%

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+71.00%

Mr. Christopher Patusky, J.D.

Lead Independent Vice Chairman of the Board

2.59K

Ms. Jan Malcolm

Director

420.00

-100.00%

Mr. Raymond C. (Ray) Kurzweil, J.D.

Independent Director

Mr. Christopher A. Causey

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

Mr. Richard A. Giltner

Independent Director

20.57K

+1190.00%

Prof. Nilda Mesa, J.D.

Independent Director

5.29K

-187.00%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

+3200.00%

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+71.00%

收入明细

单位: USD更新时间: 1月6日周二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Tyvaso DPI

336.20M

42.05%

Nebulized Tyvaso

141.80M

17.74%

Orenitram

131.10M

16.40%

Remodulin

125.90M

15.75%

Unituxin

47.90M

5.99%

其他

16.60M

2.08%

地区USD

名称

营收

占比

United States

774.80M

96.91%

Rest of World

24.70M

3.09%

业务

地区

业务USD

名称

营收

占比

Tyvaso DPI

336.20M

42.05%

Nebulized Tyvaso

141.80M

17.74%

Orenitram

131.10M

16.40%

Remodulin

125.90M

15.75%

Unituxin

47.90M

5.99%

其他

16.60M

2.08%

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

10.22%

BlackRock Institutional Trust Company, N.A.

9.90%

Renaissance Technologies LLC

5.05%

Avoro Capital Advisors LLC

4.70%

State Street Investment Management (US)

4.47%

其他

65.68%

持股股东

占比

The Vanguard Group, Inc.

10.22%

BlackRock Institutional Trust Company, N.A.

9.90%

Renaissance Technologies LLC

5.05%

Avoro Capital Advisors LLC

4.70%

State Street Investment Management (US)

4.47%

其他

65.68%

股东类型

持股股东

占比

Investment Advisor

42.36%

Investment Advisor/Hedge Fund

33.75%

Hedge Fund

13.61%

Research Firm

2.96%

Pension Fund

2.92%

Individual Investor

1.84%

Bank and Trust

1.38%

Sovereign Wealth Fund

1.29%

Venture Capital

0.46%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

1381

42.69M

99.14%

-3.71M

2025Q3

1348

44.10M

102.42%

-3.87M

2025Q2

1338

46.42M

102.62%

-2.51M

2025Q1

1369

46.67M

103.49%

-1.81M

2024Q4

1344

46.07M

102.60%

-3.00M

2024Q3

1278

45.38M

101.97%

-7.63M

2024Q2

1219

48.02M

108.26%

-2.92M

2024Q1

1151

47.12M

106.59%

-2.41M

2023Q4

1127

46.52M

99.01%

-2.26M

2023Q3

1094

46.35M

98.80%

-3.96M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

4.40M

10.22%

-31.08K

-0.70%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

4.26M

9.9%

-76.88K

-1.77%

Sep 30, 2025

Renaissance Technologies LLC

2.17M

5.05%

+54.30K

+2.56%

Sep 30, 2025

Avoro Capital Advisors LLC

2.02M

4.7%

-347.78K

-14.67%

Sep 30, 2025

State Street Investment Management (US)

1.92M

4.47%

-244.90K

-11.30%

Sep 30, 2025

Wellington Management Company, LLP

1.40M

3.25%

-44.16K

-3.06%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.25M

2.9%

+49.30K

+4.11%

Sep 30, 2025

AQR Capital Management, LLC

986.48K

2.29%

-286.68K

-22.52%

Sep 30, 2025

Darwin Global Management Ltd

748.55K

1.74%

+748.55K

Sep 30, 2025

LSV Asset Management

686.71K

1.59%

-177.91K

-20.58%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Simplify Health Care ETF

5.9%

Formidable Fortress ETF

4.22%

Franklin Genomic Advancements ETF

4.09%

First Trust NASDAQ Pharmaceuticals ETF

3.87%

Invesco Pharmaceuticals ETF

3.85%

Invesco Biotechnology & Genome ETF

3.82%

Invesco S&P MidCap Quality ETF

3.74%

Inspire Growth ETF

3.7%

VanEck Biotech ETF

3.58%

First Trust NYSE Arca Biotechnology Index Fund

3.4%

Simplify Health Care ETF

占比5.9%

Formidable Fortress ETF

占比4.22%

Franklin Genomic Advancements ETF

占比4.09%

First Trust NASDAQ Pharmaceuticals ETF

占比3.87%

Invesco Pharmaceuticals ETF

占比3.85%

Invesco Biotechnology & Genome ETF

占比3.82%

Invesco S&P MidCap Quality ETF

占比3.74%

Inspire Growth ETF

占比3.7%

VanEck Biotech ETF

占比3.58%

First Trust NYSE Arca Biotechnology Index Fund

占比3.4%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

United Therapeutics Corp的前五大股东是谁？



United Therapeutics Corp 的前五大股东如下：
The Vanguard Group, Inc.持有股份：4.40M，占总股份比例：10.22%。
BlackRock Institutional Trust Company, N.A.持有股份：4.26M，占总股份比例：9.90%。
Renaissance Technologies LLC持有股份：2.17M，占总股份比例：5.05%。
Avoro Capital Advisors LLC持有股份：2.02M，占总股份比例：4.70%。
State Street Investment Management (US)持有股份：1.92M，占总股份比例：4.47%。